New CDC Data Dashboard Shows Emerging Fentanyl and Polysubstance Use Trends
Centers for Disease Control and Prevention
 |
|---|
New CDC Data Dashboard Shows Emerging Fentanyl and Polysubstance Use Trends |
|---|
 |
|---|
CDC’s Division of Overdose Prevention recently launched the Clinical Drug Test Dashboard. This new interactive tool provides actionable data and timely insights into trends from fentanyl, heroin, cocaine, and methamphetamine, with a focus on the primary drivers of overdose deaths. The dashboard shows results from clinical urine drug tests ordered as part of routine care for adults diagnosed with substance use disorders. While these data do not represent drug use rates in the U.S. population, the large volume of test results can help identify national and regional changes in drug use and co-use more quickly than many traditional data sources.
|
|---|
Learn How to Use the Dashboard Register for our webinar on Thursday, June 11 at 1:00 p.m. EDT to walk through the dashboard, hear key findings, and get your questions answered. A recording will be posted online following the webinar.
|
|---|
The Dashboard Offers:
Drug tests were conducted by Millennium Health, an accredited laboratory that supports clinicians in monitoring prescription medications, detecting illegal drug use, and assessing treatment effectiveness. The Clinical Drug Test Dashboard will be updated quarterly as new data become available. Explore the dashboard today to see what’s changing and how the data can support your overdose prevention work.
|
|---|
📢 Spread the Word — Sample Social Media Posts Help raise awareness about this new resource by sharing on your organization's social media channels. Feel free to adapt these posts to fit your voice and audience. ________________________________________ X/Twitter NEW: @CDCgov Clinical Drug Test Dashboard is now live. This dashboard shows 2024-2025 data for #fentanyl, heroin, cocaine, and methamphetamine based on clinical drug test results from adults in substance use disorder treatment. View key findings and explore the data: https://bit.ly/4cANamd ________________________________________ NEW: @CDCgov has launched the Clinical Drug Test Dashboard—an interactive data source that shows detections of fentanyl, heroin, cocaine, and methamphetamine in clinical drug tests. This dashboard can help public health and community partners spot emerging drug trends and strengthen overdose prevention and response efforts. See what the latest clinical drug test data reveal about fentanyl and polysubstance use across the US: https://bit.ly/4cANamd ____________________________________ @CDC has released a new resource to help strengthen the nation’s response to the overdose crisis. The Clinical Drug Test Dashboard is an interactive tool that provides timely national and regional insights on fentanyl, heroin, cocaine, and methamphetamine based on clinical urine drug test data through December 2025. Data will be updated quarterly. By offering earlier signals on changes in drug use and co-use, this dashboard can help public health agencies and medical and community partners to better target and tailor prevention, treatment and response efforts. View the dashboard and see how the data can support your work: https://bit.ly/4cANamd
⚠️ In Case You Missed It! |
|---|
Health Advisory: Medetomidine Found in Illegal Drug Supply Leads to Severe Withdrawal Syndrome
|
|---|
 | People may be unknowingly exposed to medetomidine — a sedative not approved for humans — when it is mixed with illegally made fentanyl. Stopping medetomidine following regular use may lead to severe withdrawal that can require emergency or intensive care. Currently, most cases of severe withdrawal syndrome have been reported in the Northeast, but detection of medetomidine in the drug supply is expanding geographically and can be found throughout the U.S. |
|---|
Clinicians should watch for signs of medetomidine exposure and severe withdrawal symptoms in patients who present to an emergency department after a suspected overdose. This is especially important in regions where medetomidine has been detected in the drug supply. Collaboration between public health agencies, medical professionals, and community organizations is essential to mitigate risks and provide appropriate care for affected individuals. Be prepared. Review the Health Alert Network (HAN) for medetomidine-related recommendations for health departments, clinicians, hospitals, laboratories, and people at risk for overdose. Additional Resources: |
|---|
|
|---|
